Molecular and clinical oncology最新文献

{"title":"Differential diagnoses and the mutational landscape of myelodysplastic/myeloproliferative neoplasm with neutrophilia: A case report.","authors":"Bernhard Strasser,&nbsp;Monika Grünberger,&nbsp;Rita Steindl,&nbsp;Sonja Heibl,&nbsp;Josef Thaler,&nbsp;Alexander Haushofer","doi":"10.3892/mco.2023.2658","DOIUrl":"https://doi.org/10.3892/mco.2023.2658","url":null,"abstract":"<p><p>Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N; previously referred to as atypical chronic myeloid leukemia) is a type of myelodysplastic syndrome/myeloproliferative neoplasm. A molecular genetic precondition for diagnosis is <i>BCR::ABL</i> negativity; further diagnostic criteria include clinicopathological assessments, such as peripheral blood leukocyte counts, the number of neutrophils and their precursors, and the presence of dysgranulopoiesis. The present case report highlights the importance of differential diagnoses with a stringent diagnostic workup according to the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. A systematic review of the literature from 2013 to 2022 covering the mutational landscape of MDS/MPN-N was also performed to highlight recent improvements in the molecular genetic diagnostics of this disease.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 2","pages":"62"},"PeriodicalIF":1.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/d1/mco-19-02-02658.PMC10345896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kallikrein-related peptidase 13 expression and clinicopathological features in lung squamous cell carcinoma.","authors":"Ryusuke Sumiya,&nbsp;Kazuhiko Yamada,&nbsp;Teruki Hagiwara,&nbsp;Satoshi Nagasaka,&nbsp;Hideki Miyazaki,&nbsp;Toru Igari,&nbsp;Yuki I Kawamura","doi":"10.3892/mco.2023.2660","DOIUrl":"https://doi.org/10.3892/mco.2023.2660","url":null,"abstract":"<p><p>Lung squamous cell carcinoma (LSCC) is associated with poor prognosis. Molecular targeting drugs have been demonstrated to be effective for lung adenocarcinoma; however, they are often not effective for LSCC. Kallikrein-related peptidase 13 (KLK13) expression enhances the malignancy of lung adenocarcinoma; however, its expression and crucial role in LSCC remain largely unknown. The present study examined the relationship between the KLK13 expression and clinicopathological features of LSCC. A total of 94 patients diagnosed with LSCC who underwent lobectomy, segmentectomy or wedge resection were selected. KLK13 expression was evaluated through immunostaining of formalin-fixed paraffin-embedded sections of surgical specimens. Of the 94 LSCC samples, 70 exhibited no KLK13 expression, while the remaining 24 exhibited ectopic expression. KLK13 expression in tumors was focal and restricted to the cytoplasm of keratinized cells. LSCC cases were classified into KLK13-negative and KLK13-positive groups, and KLK13 expression was positively associated with E-cadherin expression (P=0.0143). Associations between KLK13 expression and keratinization (P=0.0052) or absence of lymphatic vessel invasion (P=0.0603) were observed; however, these trends did not reach statistical significance. The present findings indicated that KLK13 expression in keratinized LSCC may have a protective role in lymphatic vessel invasion of LSCC, which suggests its significance for therapeutic applications against LSCC.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 2","pages":"64"},"PeriodicalIF":1.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/bd/mco-19-02-02660.PMC10407464.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience.","authors":"Ewelina Biskup,&nbsp;Céline Montavon Sartorius,&nbsp;Andreas Müller,&nbsp;Cornelia Leo,&nbsp;Catrina Uhlmann Nussbaum,&nbsp;Elena Laura Georgescu Margarint,&nbsp;Daniel Koychev,&nbsp;Alexander Schreiber,&nbsp;Christian Taverna,&nbsp;David Thorn,&nbsp;Marcus Vetter","doi":"10.3892/mco.2023.2648","DOIUrl":"https://doi.org/10.3892/mco.2023.2648","url":null,"abstract":"<p><p>Trastuzumab and pertuzumab with taxane-based chemotherapy are considered the first-line standard therapy for human epidermal growth factor receptor 2 (<i>HER2</i>)-positive metastatic breast cancer (mBC). Pertuzumab is also a later-line therapy for mBC in Switzerland, although limited safety and efficacy data are available. The present study assessed the therapeutic regimens, toxicities and clinical outcomes after second- or later-line pertuzumab therapy in patients with mBC who did not receive pertuzumab as a first-line therapy. Physicians from nine major Swiss oncology centers retrospectively completed a questionnaire for each pertuzumab-naive patient who was treated with pertuzumab as a second- or later-line therapy. Of 35 patients with HER2-positive mBC (median age, 49 years; range, 35-87 years), 14 received pertuzumab as a second-line therapy, 6 as a third-line therapy, and 15 as a fourth- or later-line therapy. A total of 20 patients (57%) died during the study period. The median overall survival was 74.2 months (95% confidence interval, 47.6-139.8 months). Grade (G) 3/4 adverse events (AEs) were reported in 14% of patients, with only 1 patient discontinuing therapy due to pertuzumab-related toxicities. The most common AE was fatigue (overall, 46%; G3, 11%). Overall, congestive heart disease occurred in 14% of patients (G3, 6%), nausea in 14% of patients (all G1), and myelosuppression in 12% of patients (G3, 6%). In conclusion, the median overall survival of patients who underwent second- or later-line pertuzumab treatment was similar to that reported for patients who underwent first-line pertuzumab treatment, and the safety profile was acceptable. These data support the use of pertuzumab for second- or later-line therapy when it was not administered as first-line therapy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"52"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/af/mco-19-01-02648.PMC10251341.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of post‑mastectomy radiotherapy in patients with T1‑2N1 breast cancer aged ≤35 years or with a positive HER‑2 status.","authors":"Mincong Wang,&nbsp;Yali Wang,&nbsp;Fei Xie,&nbsp;Hongtao Ren,&nbsp;Jing Chen,&nbsp;Zhongwei Wang","doi":"10.3892/mco.2023.2654","DOIUrl":"https://doi.org/10.3892/mco.2023.2654","url":null,"abstract":"<p><p>Post-mastectomy radiotherapy (PMRT) is highly recommended for patients with breast cancer with one to three positive nodes; however, there remains some controversy regarding its use. The present retrospective study aimed to explore which patients may be able to avoid PMRT and its associated side effects. A total of 728 patients with T1-2N1 breast cancer who were treated with or without PMRT were included in the present study. The results suggested that PMRT significantly decreased the locoregional recurrence rate (LRR) [hazard ratio (HR)=5.602, 95% confidence interval (CI)=3.139-9.998, P<0.01; 3-year LRR: 4 vs. 17%] and improved overall survival (OS) (HR=0.651, 95% CI=0.437-0.971, P=0.03; 3-year OS: 91 vs. 87%) for patients with T1-2N1 breast cancer. By contrast, PMRT had no significant effect on the distant metastasis (DM) rate (HR=0.691, 95% CI=0.468-1.019, P=0.06; 3-year DM: 10 vs. 15%). Further stratified analysis revealed that PMRT did not reduce the LRR and DM, or improve OS in patients aged ≤35 years or in those with a positive human epidermal growth factor receptor-2 (HER-2) status. The analysis of 438 patients treated with PMRT revealed that patients aged ≤35 years or those with a positive HER-2 status were more likely to experience local recurrence even following PMRT. Thus, the benefits of using PMRT in patients with T1-2N1 breast cancer who are aged ≤35 years or in those with a positive HER-2 status need to be carefully considered. Further studies are required to confirm whether this patient group may be exempted from PMRT.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"58"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/2f/mco-19-01-02654.PMC10288432.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10091361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AMIGO2 expression as a predictor of recurrence in cervical cancer with intermediate risk.","authors":"Yuki Iida,&nbsp;Mitsuhiko Osaki,&nbsp;Shinya Sato,&nbsp;Runa Izutsu,&nbsp;Heekyung Seong,&nbsp;Masayo Okawa,&nbsp;Daiken Osaku,&nbsp;Hiroaki Komatsu,&nbsp;Fuminori Taniguchi,&nbsp;Futoshi Okada","doi":"10.3892/mco.2023.2652","DOIUrl":"https://doi.org/10.3892/mco.2023.2652","url":null,"abstract":"<p><p>Patients with recurrent cervical cancer have limited treatment options and are often considered to be incurable. Since the expression of amphoterin-induced gene and open reading frame 2 (AMIGO2) in clinical samples is a prognostic factor for colorectal cancer and gastric cancer, the present aimed to elucidate whether it is also a prognostic factor for cervical cancer. Patients with primary cervical cancer who underwent radical hysterectomy or radical trachelectomy at our institution (Faculty of Medicine, Tottori University, Yonago, Japan) between September 2005 and October 2016 were retrospectively collected. Immunohistochemical analysis using a specific antibody against AMIGO2 was performed on 101 tumor samples, and the clinical characteristics, disease-free survival (DFS) and overall survival (OS) of the patients were examined. Patients in the AMIGO2-high group had a shorter 5-year DFS and OS than those in the AMIGO2-low group (P<0.001). Furthermore, AMIGO2 was an independent prognostic factor for DFS in multivariate analysis (P=0.0012). Patients in the AMIGO2-high group exhibited obvious recurrence compared with those in the AMIGO2-low group in the high-(P=0.03) and intermediate-risk groups (P=0.003). Positive lymph node metastasis, and parametrial, stromal and lymph vascular space invasion were significantly more common in AMIGO2-high patients. Taken together, AMIGO2 expression may be a predictive marker of recurrence for cervical cancer. In particular, it may be an indicator to determine the need for postoperative adjuvant therapy in intermediate-risk group patients.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"56"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/4b/mco-19-01-02652.PMC10265584.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9708999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p53 expression is associated with tumor stage, grade and subtype in patients with hepatocellular carcinoma.","authors":"Nur Rahadiani,&nbsp;Marini Stephanie,&nbsp;Alif Gilang Perkasa,&nbsp;Diah Rini Handjari,&nbsp;Ening Krisnuhoni","doi":"10.3892/mco.2023.2650","DOIUrl":"https://doi.org/10.3892/mco.2023.2650","url":null,"abstract":"<p><p>The present study aimed to determine the expression levels of p53 in patients with hepatocellular carcinoma (HCC) and to evaluate its association with several HCC-related prognostic factors and in particular, with tumor stage, grade and subtype. Therefore, a cross-sectional study, involving 41 patients with HCC, who underwent surgical resection between January, 2013 and December, 2020 was conducted. To assess the expression levels of p53 in all patients with HCC, immunohistochemical staining was performed. In addition, the association between p53 expression and the clinicopathological characteristics of patients with HCC, including prognostic factors, was evaluated by applying the appropriate statistical analysis methods. The results revealed that among the 41 patients enrolled, 35 patients (85.4%) were positive for p53 expression. A higher percentage of positive p53 expression was observed in male patients >60 years old, with single HCC nodules >5 cm in diameter and vascular invasion, compared with their counterparts. A positive p53 expression was associated with well- and poorly differentiated HCC, but not with tumor stage and subtype. No differences in p53 expression were observed across different tumor stages and subtypes. Additionally, patients with moderately and poorly differentiated HCC exhibited significantly higher p53 expression levels compared with those suffering from well-differentiated HCC. Overall, the results demonstrated that the rate of p53 immuno-positive cells was increased in patients with HCC. In addition, p53 expression was associated with well- and poorly differentiated HCC, thus suggesting its association with a poorer prognosis.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"54"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/ba/mco-19-01-02650.PMC10265582.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conservative treatment of endometrial cancer in women of reproductive age (Review).","authors":"Maria Zoi Bourou,&nbsp;Alkis Matsas,&nbsp;Thomas Vrekoussis,&nbsp;Georgios Mastorakos,&nbsp;Georgios Valsamakis,&nbsp;Theodoros Panoskaltsis","doi":"10.3892/mco.2023.2651","DOIUrl":"https://doi.org/10.3892/mco.2023.2651","url":null,"abstract":"<p><p>Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"55"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/59/mco-19-01-02651.PMC10265581.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9708997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the prevalence of atrophic gastritis and Helicobacter pylori infection over a 10‑year period in Japan: The ROAD study 2005‑2015.","authors":"Izumi Inoue,&nbsp;Noriko Yoshimura,&nbsp;Toshiko Iidaka,&nbsp;Chiaki Horii,&nbsp;Shigeyuki Muraki,&nbsp;Hiroyuki Oka,&nbsp;Hiroshi Kawaguchi,&nbsp;Toru Akune,&nbsp;Takao Maekita,&nbsp;Kanae Mure,&nbsp;Kozo Nakamura,&nbsp;Sakae Tanaka,&nbsp;Masao Ichinose","doi":"10.3892/mco.2023.2649","DOIUrl":"https://doi.org/10.3892/mco.2023.2649","url":null,"abstract":"<p><p>Few large population-based studies have examined the prevalence of atrophic gastritis (AG) and <i>Helicobacter pylori</i> infection in Japan. The purpose of the present study was to estimate the prevalence of AG and <i>H. pylori</i> infection by age, in addition to investigating their change rates from 2005 to 2016 in Japan using data from a large population-based cohort. A total of 3,596 participants [1,690 in the baseline survey (2005-2006) and 1,906 at the fourth survey (2015-2016)] aged 18 to 97 years were included in the cohort. The prevalence of AG and <i>H. pylori</i> infection were examined at baseline and in the fourth survey based on serological tests for the <i>H. pylori</i> antibody titer and pepsinogen levels. The prevalence of AG and <i>H. pylori</i> infection were 40.1% (men, 44.1%; women, 38.0%) and 52.2% (men, 54.8%; women, 50.8%), respectively, at baseline. AG seropositivity rates showed a significant decrease from 40.1 to 25.8% in 10 years. <i>H. pylori</i> seropositivity rates decreased significantly from 52.2 to 35.5% in 10 years. Stratified for age, the prevalence of AG showed an increasing trend with age, whereas the prevalence of <i>H. pylori</i> infection increased with aging, except for in the elderly group, showing an inverted U-shaped association. In this population-based, cross-sectional study with a 10-year interval survey, the prevalence of AG and <i>H. pylori</i> infection decreased significantly. This change may influence the prevalence of <i>H. pylori</i>-related diseases, including extra-gastric disorders associated with <i>H. pylori</i>-induced systemic subclinical inflammation and hypochlorhydria, such as colorectal neoplasia and arteriosclerosis.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"53"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/89/mco-19-01-02649.PMC10265571.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review.","authors":"Jie Tang,&nbsp;Xiu-Wen Li,&nbsp;Yong Wu,&nbsp;Zhen Su,&nbsp;Yan He,&nbsp;Xue-Wen Sun,&nbsp;Xiao-Long Cao,&nbsp;Yi-Hua Li,&nbsp;Bi-Cheng Wang,&nbsp;Guo-Rong Zou","doi":"10.3892/mco.2023.2653","DOIUrl":"https://doi.org/10.3892/mco.2023.2653","url":null,"abstract":"<p><p>Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"57"},"PeriodicalIF":1.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/b0/mco-19-01-02653.PMC10288433.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9705683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurements of target volumes and organs at risk using DW‑MRI in patients with central lung cancer accompanied with atelectasis.","authors":"Xinli Zhang,&nbsp;Tong Liu,&nbsp;Hong Zhang,&nbsp;Mingbin Zhang","doi":"10.3892/mco.2023.2641","DOIUrl":"https://doi.org/10.3892/mco.2023.2641","url":null,"abstract":"<p><p>Accurate imaging-based tumor delineation is crucial for guiding the radiotherapy treatments of various solid tumors. Currently, several imaging procedures, including diffusion-weighted magnetic resonance imaging (DW-MRI), intensified computed tomography and positron emission tomography are routinely used for targeted tumor delineation. However, the performance of these imaging procedures has not yet been comprehensively evaluated. In order to address this matter, the present study was conducted in an aim to assess the use of DW-MRI in guiding radiotherapy treatments, by comparing its performance to that of other imaging procedures. Specifically, the exposure dosages to organs at risk, including the lungs, heart and spinal mencord, were evaluated using various radiotherapy regimes. The findings of the present study demonstrated that DW-MRI is a non-invasive and cost-effective imaging procedure that can be used to reduce lung exposure doses, minimizing the risk of radiation pneumonitis. The data further demonstrate the immense potential of the DW-MRI procedure in the precision radiotherapy of lung cancers.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 6","pages":"45"},"PeriodicalIF":1.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/7c/mco-18-06-02641.PMC10155240.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}